DPD Genotype
The DPD genotype measures variations in the DPYD gene, which encodes the enzyme dihydropyrimidine dehydrogenase (DPD) involved in the metabolism of fluoropyrimidine drugs.
DPD genotype predicts individual response to fluoropyrimidine chemotherapy drugs.
Key facts at a glance
- Units
- genotype
- Clinical utility
- predictive
- Result kind
- qualitative
- FDA-cleared
- Roche AmpliChip DPYD, Abbott Infiniti DPYD, AutoGenomics DPYD
The DPYD gene provides instructions for making the DPD enzyme, which is crucial for breaking down fluoropyrimidine drugs like 5-fluorouracil (5-FU) used in cancer treatment.
Variations in the DPYD gene can lead to reduced or absent DPD enzyme activity, resulting in increased drug toxicity and adverse effects in patients.
Testing for DPD genotype helps clinicians adjust drug dosages or choose alternative treatments to minimize toxicity risks and improve treatment outcomes.
Frequently asked questions
What are the risks of not testing for DPD genotype?
How is DPD genotype testing performed?
Sources
- 1
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy